Obesity Overview
Obesity is recognized as a chronic or non-communicable disease, a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity or body fatness which can manifest metabolically and not just concerning the size of the body.
“Obesity Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.
The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Obesity Pipeline Report:
Route of Administration
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Molecule Type
Products have been categorized under various Molecule types, such as
Obesity Pipeline Therapeutics Assessment
DelveInsight’s Obesity Report covers around products under different phases of clinical development like
Some of the key companies in the Obesity Therapeutics Market include:
Key companies developing therapies for Obesity are – ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company, and others.
Emerging Obesity Drugs Under Different Phases of Clinical Development Include:
Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/obesity-pipeline-insight
Obesity Pipeline Analysis:
The Obesity pipeline report provides insights into
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies
Obesity Pipeline Market Drivers
Obesity Pipeline Market Barriers
Scope of Obesity Pipeline Drug Insight
Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials
Table of Contents
1
Obesity Report Introduction
2
Obesity Executive Summary
3
4
Obesity- Analytical Perspective In-depth Commercial Assessment
5
Obesity Pipeline Therapeutics
6
Obesity Late Stage Products (Phase II/III)
7
Obesity Mid Stage Products (Phase II)
8
Obesity Early Stage Products (Phase I)
9
Obesity Preclinical Stage Products
10
Obesity Therapeutics Assessment
11
Obesity Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Obesity Key Companies
14
Obesity Key Products
15
Obesity Unmet Needs
16
Obesity Market Drivers and Barriers
17
Obesity Future Perspectives and Conclusion
18
Obesity Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Obesity drugs and therapies
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting